In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Clinical Trials - Hot Lines

ESC Congress 2021 - The Digital Experience, from 27 to 30 August

Your first-access to ground-breaking cardiovascular science in a new digital experience.

From Friday to Monday, tune in to the Prime Time programme from 14:00 (CEST).

Major clinical trials and updates will be given centre stage from the studio.

Register now to join us, live from the ESC studio

  • Be the first to hear the latest on cardiovascular care from the presenters
  • Learn more through analysis and discussion from our expert panels
  • Get YOUR questions answered, live from the studio!

and receive full access to all presentations, on-demand, until 13 September.




Hot Lines sessions are reserved for first presentation of the primary endpoint(s) of novel clinical trials, recently completed and unpublished

These presentations will be complemented by a deep dive into the data during discussions with the trialists and insights from key opinion leaders


Friday, 27 August

GUIDE-HF: haemodynamic-guided management of heart failure – randomised arm primary outcomes

EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes

EMPEROR-Pooled: effect of empagliflozin on serious adverse renal outcomes in chronic heart failure – a prospective alpha-protected, Individual patient-level pooled analysis 

SMART-MI- ICMs: Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction - A randomized trial

Saturday, 28 August

MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation

FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes

FIDELITY Analysis: finerenone in mild-to-severe chronic kidney disease and type 2 diabetes

APAF-CRT: AV junction ablation and CRT in patients with permanent atrial fibrillation and narrow QRS

DECAAF II: efficacy of DE-MRI-guided fibrosis ablation vs. conventional catheter ablation of persistent atrial fibrillation

Sunday, 29 August

TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest

RIPCORD 2: does routine pressure wire assessment influence management strategy of coronary angiography for diagnosis of chest pain?

ACST-2: stenting vs. surgery for tight carotid stenosis

LOOP Study: screening for AF with an implantable loop recorder to prevent stroke

SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death

Monday, 30 August

IAMI: Influenza Vaccination after Myocardial Infarction randomised trial

PRONOUNCE: comparing cardiovascular safety of degarelix vs. leuprolide in patients with advanced prostate cancer and cardiovascular disease

STEP Study: intensive vs. standard blood pressure control among older hypertensive patients

Amulet IDE: Amplatzer Amulet left atrial appendage occluder randomised controlled trial

STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome


Even more Late-Breaking Science in the channels and on-demand programmes.

See them all.


See the full programme


Register now

And get full access to all presentations on-demand until 13 September.

Register now